The direct answer
Botulinum Toxin Type A (such as Botox, Dysport, Xeomin, Jeuveau, and Daxxify) and Botulinum Toxin Type B (Myobloc) are distinct neurotoxin serotypes that target different proteins in the nerve terminal to inhibit the release of acetylcholine.
Type A toxins cleave SNAP-25 and typically maintain a duration of effect of 3 to 4 months. In contrast, Type B (Myobloc) cleaves VAMP (also known as synaptobrevin), exhibits a faster clinical onset of 24 to 48 hours, but has a significantly shorter duration of action of 4 to 8 weeks for most cosmetic applications.
Furthermore, Myobloc is formulated as a highly acidic liquid solution (pH 5.6) that causes a distinct stinging sensation upon injection, and it carries a higher affinity for autonomic cholinergic receptors, leading to higher rates of systemic dry mouth (xerostomia) and mild swallowing difficulty (dysphagia). Because of these characteristics, Myobloc is primarily utilized as a specialized therapeutic tool—particularly for patients who have developed immunoresistance to Type A toxins—rather than a first-line cosmetic neuromodulator.
For a deeper dive into the longevity and dosage patterns of standard botulinum toxin type A injections, see our guide on how long Botox lasts.
Molecular Mechanisms: SNAP-25 vs. VAMP (Synaptobrevin)
Both botulinum toxin type A and type B are zinc-dependent metalloendopeptidases produced by the bacterium Clostridium botulinum. They share a similar structural template, consisting of a 150 kDa di-chain polypeptide: a 100 kDa heavy chain responsible for cell receptor binding and internalization, and a 50 kDa light chain that acts as the intracellular protease.
However, once the light chain is translocated across the endosomal membrane into the cytosol of the motor nerve terminal, the two serotypes diverge fundamentally in their enzymatic target within the SNARE (Soluble NSF Attachment Protein Receptor) protein complex. The SNARE complex is the physical machinery that enables synaptic vesicles containing acetylcholine to dock with the presynaptic membrane and release their contents into the neuromuscular junction.
Presynaptic Terminal Membrane
┌──────────────────────────────────────────────────────────┐
│ [SNARE Complex] │
│ │
│ [Synaptic Vesicle] [Cell Membrane] │
│ (Acetylcholine) (SNAP-25) │
│ │ │ │
│ ▼ ▼ │
│ [VAMP] <── cleaved by Type B │ │
│ │ (RimabotulinumtoxinB) │ │
│ ▼ │ │
│ [Syntaxin] │ │
│ │ │ │
│ └───────────────────────── Cleaved by Type A │
│ (OnabotulinumtoxinA)│
└──────────────────────────────────────────────────────────┘
Type A Mechanism: Cleaving SNAP-25
Type A neuromodulators—including OnabotulinumtoxinA (Botox), AbobotulinumtoxinA (Dysport), IncobotulinumtoxinA (Xeomin), PrabotulinumtoxinA-xvfs (Jeuveau), and DaxibotulinumtoxinA-lanm (Daxxify)—bind to SV2 (synaptic vesicle protein 2) receptors. Once inside the cytoplasm, the light chain specifically targets and cleaves SNAP-25 (Synaptosomal-Associated Protein of 25 kDa) at the C-terminus (specifically the peptide bond between glutamine-197 and arginine-198). Cleavage of SNAP-25 prevents the assembly of the core SNARE complex, halting vesicular docking and exocytosis of acetylcholine.
Type B Mechanism: Cleaving VAMP (Synaptobrevin)
Type B neuromodulator—commercially available as RimabotulinumtoxinB (Myobloc)—utilizes a different cell entry pathway, binding primarily to synaptotagmin I and II in the presence of gangliosides. Once translocated into the cytosol, the Type B light chain cleaves VAMP (Vesicle-Associated Membrane Protein), also known as synaptobrevin, at a single peptide bond between proline-76 and glutamine-77. Since VAMP is located on the vesicle membrane itself (rather than the plasma membrane like SNAP-25), its cleavage disrupts vesicle-to-membrane fusion from the vesicular side.
This difference in intracellular targets is critical. Because Type A and Type B cleave completely different proteins, they do not compete for the same molecular sites. If a patient develops neutralizing antibodies against SNAP-25-cleaving Type A toxins, their VAMP-cleaving machinery remains fully functional. This molecular independence forms the scientific basis for switching patients to Type B when they become clinically unresponsive to Type A.
FDA Approval Histories and Regulatory Path
The regulatory pathways for Type A and Type B toxins in the United States reflect their different clinical utilities and commercial development histories.
Botox (OnabotulinumtoxinA)
Approved under Biologics License Application BLA 103000 by Allergan (now AbbVie), Botox was first cleared by the FDA in December 1989 for therapeutic indications (strabismus and blepharospasm). The regulatory milestone for aesthetic medicine occurred on April 12, 2002, when the FDA approved Botox Cosmetic for the temporary improvement in the appearance of moderate to severe glabellar lines. Over the subsequent two decades, its approved indications expanded to include crow's feet (lateral canthal lines) in 2013 and forehead lines in 2017, alongside numerous therapeutic approvals (chronic migraine, cervical dystonia, axillary hyperhidrosis, overactive bladder, and upper limb spasticity).
Myobloc (RimabotulinumtoxinB)
Approved under Biologics License Application BLA 103846 (originally developed by Solstice Neurosciences and now marketed by US WorldMeds, LLC), Myobloc received its initial FDA approval on December 8, 2000, for the treatment of cervical dystonia to reduce the severity of abnormal head position and neck pain. In August 2019, the FDA expanded Myobloc’s indications to include chronic sialorrhea (excessive drooling) in adults — making it the first and only Type B botulinum toxin approved for that use.
Unlike Botox, Myobloc has never received an FDA clearance or approval for cosmetic indications. Any use of Myobloc for facial wrinkle reduction, jaw slimming, or other aesthetic procedures is entirely off-label. While off-label clinical use is common and legal under the professional judgment of licensed injectors, it lacks the formal safety and efficacy backing of large-scale cosmetic clinical trials.
Non-Interchangeability and Dosing Math
A fundamental rule of botulinum toxin regulation is that dosing units are not interchangeable. One Unit of Botox does not equal one Unit of Myobloc, nor does it equal one Unit of Dysport or Xeomin.
┌───────────────────────────────────────────────────────────┐
│ Dosing Equivalence Warning │
├───────────────────────────────────────────────────────────┤
│ Botox (Type A) Dosing Units ≠ Myobloc (Type B) Units │
│ │
│ Clinical Conversion Ratio: │
│ 1 Unit of Botox ≈ 50 to 100 Units of Myobloc │
│ │
│ *Never convert doses using a 1:1 ratio. Doing so can │
│ result in severe under-dosing or fatal toxicity. │
└───────────────────────────────────────────────────────────┘
In clinical practice, the potency ratio between Type A and Type B is massive. The generally accepted conversion ratio ranges from 1:50 to 1:100. For example, a patient receiving 20 Units of Botox for a therapeutic indication might require 1,000 to 2,000 Units of Myobloc to achieve a comparable neuromuscular blockade. Because of this non-equivalence, medical documentation must clearly state the specific brand name and exact units injected, and injectors must never attempt to substitute these products on a one-to-one unit basis.
Physicochemical Properties and Injection Comfort
The physical properties and chemical formulations of Botox and Myobloc dictate their storage requirements, preparation workflows, and patient experiences.
Reconstitution vs. Liquid-Ready
- Botox (Type A): Supplied as a vacuum-dried, sterile powder containing 50, 100, or 200 Units of onabotulinumtoxinA, stabilized with human albumin and sodium chloride. It requires reconstitution prior to injection using sterile, preservative-free or preserved 0.9% Normal Saline. Once reconstituted, the solution has a physiological pH of approximately 7.2 to 7.4.
- Myobloc (Type B): Supplied as a ready-to-use, clear and colorless to light-yellow sterile liquid solution. It does not require reconstitution, removing preparation steps and minimizing dilution errors in the clinic. However, to maintain the stability of the Type B toxin in liquid form, it must be formulated in an acidic buffer.
The Stinging Profile: Acidic pH 5.6
According to the Myobloc Prescribing Information, the drug is formulated as an acidic solution containing rimabotulinumtoxinB, human serum albumin, sodium succinate, and sodium chloride at a pH of approximately 5.6.
Injecting a solution with a pH of 5.6 into the dermis or muscle tissue causes an immediate, sharp stinging or burning sensation. Because physiological tissues operate at a neutral pH (7.4), the sudden introduction of an acidic fluid stimulates local nociceptors (pain receptors). Patients routinely report that Myobloc injections are significantly more painful than Botox injections. To mitigate this discomfort, some providers perform nerve blocks or use topical anesthetics, but the physical sensation remains a significant barrier to its widespread cosmetic adoption.
Stability and Shelf Life
While Botox must be used within 24 hours of reconstitution to ensure potency (according to the manufacturer's label, though clinical practice often extends this slightly), Myobloc has a long shelf life as a liquid. Unopened vials of Myobloc remain stable for up to 36 months when stored under refrigeration at 2°C to 8°C (36°F to 46°F). Once the vial is punctured, however, it contains no preservatives and must be used or discarded within 4 hours.
Clinical Performance: Onset, Duration, and Diffusion
When comparing the clinical performance of Type A and Type B neuromodulators, three parameters define their utility: how fast they work, how long they last, and how far they spread.
| Performance Parameter | Type A (e.g., Botox Cosmetic) | Type B (Myobloc) |
|---|---|---|
| FDA Approval Status | Labeled for Cosmetic & Therapeutic | Labeled for Therapeutic Only |
| Active Serotype | Botulinum Toxin Type A | Botulinum Toxin Type B |
| Preparation | Vacuum-dried powder; requires saline | Ready-to-use liquid |
| Reconstituted pH | ~7.2 to 7.4 (Physiological) | ~5.6 (Acidic; stings on injection) |
| Clinical Onset | 3 to 7 days (Full effect at 14 days) | 24 to 48 hours |
| Duration of Action | 3 to 4 months (up to 6 months with Daxxify) | 4 to 8 weeks (Aesthetic); 12-16 weeks (Dystonia) |
| Radius of Diffusion | Moderate (~1.0 cm to 1.5 cm) | High (~2.0 cm to 2.5 cm) |
| Primary Indication | Glabellar, Crow's Feet, Forehead | Cervical Dystonia, Sialorrhea |
Rapid Onset
Myobloc exhibits a exceptionally fast clinical onset. Patients often notice muscle relaxation and sweat reduction within 24 to 48 hours of injection. In comparison, Type A toxins typically require 3 to 7 days to show initial effects, with full clinical results establishing at 14 days. The rapid onset of Type B is hypothesized to result from a higher rate of cellular internalization or a faster intracellular cleavage rate of VAMP compared to SNAP-25, making it attractive for patients seeking rapid symptom relief.
Shorter Duration of Action
The major disadvantage of Myobloc in cosmetic practice is its short duration. In aesthetic applications, the wrinkle-smoothing effect of Myobloc begins to fade within 4 to 8 weeks, requiring more frequent treatments to maintain results. For comparison, standard Type A toxins last 12 to 16 weeks, and peptide-stabilized Type A (Daxxify) can last up to 24 weeks.
Interestingly, Myobloc's therapeutic duration for cervical dystonia is longer, typically lasting 12 to 16 weeks. This difference is due to the higher doses used in therapeutic settings, which saturate the nerve terminals more completely, extending the time required for the body to regenerate functional neuromuscular junctions.
Radius of Diffusion
Myobloc has a larger radius of diffusion than Botox. When injected into tissue, Type B spreads further from the needle tip (often diffusing over an area of 2.0 to 2.5 cm, compared to 1.0 to 1.5 cm for Botox).
- When diffusion is beneficial: A higher diffusion rate is useful when treating large, flat muscle areas (such as the platysma bands in the neck) or when targeting diffuse sweating in the underarms (hyperhidrosis) or palms. It allows the injector to cover a larger surface area with fewer needle punctures.
- When diffusion is risky: In the face, precise placement is essential to avoid paralyzing adjacent muscles. The high diffusion rate of Myobloc increases the risk of the toxin migrating to unintended muscles, potentially causing cosmetic complications such as eyelid ptosis (drooping eyelid), brow drop, or an asymmetric smile. Consequently, using Myobloc in the delicate periorbital or perioral regions requires advanced injection techniques.
Safety Profiles and FAERS Database Analysis
All botulinum neuromodulators are biologically active proteins that carry risks of adverse events. However, post-market surveillance data reveals distinct safety profiles for Type A and Type B toxins.
Systemic Adverse Events in FAERS
The FDA Adverse Event Reporting System (FAERS) is a database containing post-market safety reports submitted by healthcare professionals, manufacturers, and consumers. In a June 2026 extract of the FDA FAERS database, the reporting volumes differ dramatically between these products:
- Myobloc (Type B): Associated with 45 adverse event reports in that extract. While this is a low absolute volume reflecting its smaller market share, a high percentage of these reports involve systemic anticholinergic events and are classified as serious.
- Botox and Botox Cosmetic (Type A): Combined, they represent 76,371 reports (37,351 for Botox and 39,020 for Botox Cosmetic), reflecting their dominant commercial footprint over more than two decades of clinical use.
The safety data must be interpreted within the context of passive surveillance: FAERS reports represent suspected associations and do not prove direct causality. However, the concentration of specific symptoms in Type B reports aligns with the known pharmacology of RimabotulinumtoxinB.
Autonomic Cholinergic Receptor Affinity
Type B botulinum toxin has a significantly higher affinity for the autonomic nervous system—specifically the cholinergic receptors that control involuntary functions like salivation and pupillary constriction—compared to Type A. Because Type B binds more readily to these receptors, systemic absorption leads to a higher rate of autonomic side effects:
- Xerostomia (Severe Dry Mouth): Dry mouth was the most common adverse reaction in Myobloc cervical dystonia trials, occurring in up to 34% of patients at the 10,000-Unit dose (versus 3% on placebo in the same trial), with severe dry mouth reported by about 6% of patients. In the FAERS database, xerostomia is a prominent safety signal for Myobloc.
- Dysphagia (Swallowing Difficulty): Swallowing difficulty is a recognized risk of all neuromodulators, but it occurs with greater frequency and severity in patients receiving Type B. Dysphagia was reported in up to 25% of patients in Myobloc cervical dystonia trials (at the 10,000-Unit dose), a higher rate than typically seen with Type A toxins.
- Dysphonia (Voice Changes/Hoarseness): The spread of Type B toxin into the laryngeal muscles can cause hoarseness or a weak voice.
The FDA Boxed Warning: Distant Toxin Spread
Like all botulinum products, Myobloc and Botox carry a class-wide FDA Boxed Warning. The warning states that the effects of the botulinum toxin may spread from the area of injection to produce symptoms consistent with botulism. These symptoms include asthenia (generalized muscle weakness), generalized double vision, blurred vision, ptosis, difficulty swallowing, speech difficulty, and life-threatening breathing difficulties.
┌────────────────────────────────────────────────────────────┐
│ FDA BOXED WARNING SUMMARY │
├────────────────────────────────────────────────────────────┤
│ Risk of Distant Toxin Spread: │
│ - Symptoms can appear hours to weeks post-injection. │
│ - Includes swallowing and breathing difficulties. │
│ - Can be fatal; seek immediate medical attention if │
│ swallowing, speech, or respiratory problems arise. │
└────────────────────────────────────────────────────────────┘
Because of Myobloc's higher diffusion rate and autonomic affinity, patients receiving large therapeutic doses must be monitored closely for systemic signs of spread, and providers must document that patients have been counseled on these risks prior to injection. For a detailed breakdown of the FDA labels, boxed warnings, and contraindications of aesthetic injectables, see our comprehensive guide on FDA injectable labels and boxed warnings.
Clinical Scenarios and Patient Selection: When is Myobloc Used?
Given Myobloc's acidic pH, high injection discomfort, short duration, and higher side-effect profile, its use is carefully restricted to specific clinical scenarios.
1. True Type A Immunoresistance (Antibody Formation)
The primary clinical indication for using Myobloc in both therapeutic and off-label cosmetic practice is antibody-mediated resistance to Type A toxins.
Over multiple treatment cycles, a small percentage of patients (estimated at less than 1% for cosmetic patients, but up to 5-10% for high-dose therapeutic patients) develop neutralizing antibodies against the Type A protein or its accessory proteins. When this occurs, the patient experience "treatment failure"—the Type A toxin no longer relaxes the muscle, even at escalated doses.
Because Type B has an entirely different amino acid sequence and cleaves a different target protein (VAMP instead of SNAP-25), the patient's Type A antibodies cannot neutralize Myobloc. Switching to Myobloc allows these immunoresistant patients to resume successful neuromodulator therapy.
2. Treatment of Sialorrhea (Drooling)
Myobloc is FDA-approved and highly effective for chronic sialorrhea (excessive drooling) in adults, which is common in neurological conditions such as Parkinson's disease, ALS, or post-stroke syndrome.
In this scenario, Myobloc's high affinity for autonomic cholinergic receptors is a clinical benefit. By injecting Myobloc directly into the parotid and submandibular salivary glands, providers can suppress salivation. The toxin's high diffusion rate helps it spread evenly throughout the glandular tissue, providing relief that lasts up to 16 weeks.
3. Cervical Dystonia
For patients with cervical dystonia (involuntary neck muscle contractions), Myobloc provides rapid relief of abnormal head positioning and neck pain. Its high diffusion rate allows a single injection to cover large neck muscles (such as the splenius capitis or sternocleidomastoid), reducing the number of needle insertions required.
4. Severe Hyperhidrosis (Off-Label)
For patients with severe underarm or palmar sweating who are unresponsive to topical treatments, Myobloc's autonomic affinity and high diffusion rate make it a powerful off-label tool. The injector can cover the entire axillary vault or palm with fewer injection points. The rapid 24-hour onset provides fast relief, though patients must be counseled on the temporary stinging during the procedure and the potential for a shorter duration of sweat control compared to Botox.
FAQs
Why does Myobloc hurt more to inject than Botox?
Myobloc is pre-formulated by the manufacturer as a liquid solution with an acidic pH of 5.6 to preserve its molecular stability. Reconstituted Botox has a physiological pH of approximately 7.2 to 7.4. When the acidic Myobloc solution is injected, it temporarily alters the local tissue pH, stimulating nociceptors and causing a sharp stinging sensation that is not felt with neutral-pH injections.
Can you switch to Myobloc if you become resistant to Botox?
Yes. If you have developed neutralizing antibodies that make you clinically resistant to Type A toxins (Botox, Xeomin, Dysport, Jeuveau), you can switch to Myobloc. Because Type B (Myobloc) has a different molecular structure and cleaves VAMP instead of SNAP-25, your Type A antibodies will not neutralize it, restoring the clinical effectiveness of your treatments.
Is Myobloc approved for cosmetic use?
No. The FDA has approved Myobloc only for therapeutic indications (cervical dystonia and chronic sialorrhea). Any cosmetic use of Myobloc (such as wrinkle reduction or jaw slimming) is off-label. While off-label use is common, patients should verify their injector's experience with Type B toxins, as their high diffusion rate requires precise technique.
How does the duration of Myobloc compare to Botox for cosmetic treatments?
For cosmetic wrinkle reduction, Myobloc has a significantly shorter duration of action, typically lasting only 4 to 8 weeks, compared to 3 to 4 months for Botox. This shorter duration is due to how quickly the body regenerates the VAMP proteins cleaved by Type B compared to the SNAP-25 proteins cleaved by Type A.
Can Myobloc and Botox units be substituted 1-for-1?
No. Dosing units are not interchangeable. Myobloc is significantly less potent per unit than Botox. The clinical conversion ratio ranges from 1:50 to 1:100, meaning a patient who requires 20 Units of Botox would need 1,000 to 2,000 Units of Myobloc to achieve the same effect. Always consult an experienced provider who understands these dosing differences.
Sources
- FDA. BOTOX Cosmetic (onabotulinumtoxinA) Prescribing Information. BLA 103000. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103000
- FDA. MYOBLOC (rimabotulinumtoxinB) Prescribing Information. BLA 103846. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103846
- National Library of Medicine. MYOBLOC (rimabotulinumtoxinB) Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b7cbe71-4770-4f51-b0db-b27bcfb92d6e
- Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. PubMed 16275831. https://pubmed.ncbi.nlm.nih.gov/16275831/
- FDA Adverse Event Reporting System (FAERS), June 2026 extract. U.S. Food and Drug Administration.
